Lumbar spinal stenosis (LSS) is one of the most common causes of pain and disability in older adults. Characterized by narrowing of the spinal canal that compresses neural elements, it classically produces neurogenic claudication that presents itself with leg pain, numbness, or weakness provoked by standing or walking and relieved by sitting or flexion. With an estimated prevalence of 11 percent among older adults in the United States and more than 100 million people affected worldwide, LSS represents a major clinical and economic burden.
Fortunately, a growing body of evidence supports a stepped, patient-centered approach that prioritizes nonoperative care and reserves surgery for those who remain significantly limited. This article reviews the current evidence across the treatment continuum: neuromodulating medications, core strengthening and multimodal physical therapy, epidural injections, the minimally invasive lumbar decompression (MILD) procedure, interspinous spacers, and open surgical decompression.
Natural history and the rationale for stepped care
Not all patients with radiographic stenosis require aggressive intervention. Observational data show that over 3 years, approximately one-third of patients improve, half remain stable, and only 10 to 20 percent worsen. This favorable natural history underpins guidelines from the North American Spine Society (NASS) and others that recommend initial medical and interventional management for patients with moderate symptoms.
Real physician voices, twice a week
Free, and one click to unsubscribe.
Neuromodulating medications
Gabapentin and pregabalin are commonly prescribed for the neuropathic component of LSS-related leg pain. However, high-quality evidence does not support their routine use. A recent double-blind randomized placebo-controlled trial found that neither gabapentin (up to 1,800 mg/day) nor pregabalin (up to 300 mg/day) was superior to placebo for neurogenic claudication, walking distance, or functional outcomes when added to standard conservative care. Both agents were associated with significantly higher rates of dizziness and sedation.
Systematic reviews and meta-analyses confirm limited short-term benefit and a higher adverse-event profile. Clinical practice guidelines therefore recommend against the routine use of gabapentinoids for LSS with neurogenic claudication, reserving them for carefully selected patients with refractory neuropathic features after other measures have been optimized.
Core strengthening and multimodal physical therapy
Supervised exercise programs that emphasize core stabilization, flexion-based movements, manual therapy, education, and progressive walking training have the strongest nonoperative evidence base. Moderate-quality evidence from randomized trials demonstrates that a structured 6-week multimodal program produces superior and clinically meaningful improvements in pain, function, and walking distance compared with medical care alone or self-directed home exercise.
These programs are safe, cost-effective, and can yield long-term outcomes comparable to surgery in selected patients. Clinicians should emphasize supervised rather than purely self-directed exercise, as adherence and proper technique significantly influence results.
Epidural steroid injections
Epidural injections remain one of the most frequently performed interventions for LSS. A large randomized trial of 400 patients demonstrated that the addition of corticosteroid to lidocaine produced modest short-term (3-week) improvement in pain and function, but no clinically meaningful or sustained benefit at 6 weeks, 12 weeks, or 12 months compared with lidocaine alone.
Guidelines reflect this evidence: NASS cites fair evidence for short-term relief and poor-quality evidence for longer-term benefit. Epidural injections may serve as a temporary bridge to facilitate physical therapy or as a diagnostic trial, but they should not be viewed as definitive long-term therapy.
Minimally invasive lumbar decompression (MILD)
The MILD procedure is a percutaneous, image-guided technique that removes hypertrophied ligamentum flavum through a small portal, thereby expanding the central canal. Multiple prospective studies and randomized trials have shown statistically and clinically significant improvements in pain scores, Oswestry Disability Index, and claudication symptoms that are maintained at 1 to 2 years. Safety profiles are favorable, with adverse-event rates comparable to epidural injections and low rates of subsequent open surgery.
MILD is best suited to patients with predominant central stenosis due to ligamentum flavum hypertrophy who have failed conservative care and are higher-risk surgical candidates. Proper patient selection remains critical; recent comparative imaging studies have questioned the degree of anatomic decompression relative to open laminectomy, reinforcing the need for realistic expectations.
Interspinous process spacers (Superion and related devices)
Standalone interspinous spacers provide indirect decompression by limiting extension while preserving flexion. The Superion device, supported by level 1 evidence from a large FDA investigational device exemption trial, has demonstrated durable improvements in leg and back pain, Zurich Claudication Questionnaire scores, and function through 4 to 5 years in patients with moderate LSS and neurogenic claudication who experience relief with flexion.
These devices offer a less invasive alternative for appropriately selected patients without significant instability or severe stenosis. Reoperation rates are moderate, and careful patient counseling regarding expectations is essential.
Surgical decompression
When disabling symptoms persist despite optimized nonoperative and minimally invasive care, open or minimally invasive laminectomy (with or without fusion) remains the gold-standard surgical option. Randomized trials have shown greater early improvement in pain and function with decompression compared with continued nonoperative care in carefully selected patients. Recent noninferiority data indicate that decompression alone is often sufficient; routine fusion for pure stenosis without instability or deformity is not supported.
Surgery is elective in nearly all cases. Patients should understand that while early gains can be substantial, long-term differences may narrow, and reoperation rates of 10 to 20 percent at 5 to 8 years are reported.
Practical clinical takeaways
- Begin with supervised multimodal physical therapy focused on core strengthening and flexion-based exercise.
- Use gabapentinoids and epidural steroids selectively and for limited duration.
- Consider MILD or interspinous spacers for moderate, flexion-responsive stenosis in patients who are not ideal open-surgery candidates.
- Reserve open decompression for patients with persistent, lifestyle-limiting symptoms after a thorough trial of less invasive options.
- Shared decision-making that incorporates patient goals, comorbidities, imaging, and realistic expectations is essential at every step.
LSS management has evolved beyond a binary choice between “conservative care” and “surgery.” An evidence-based, stepped approach allows most patients to achieve meaningful improvement while minimizing unnecessary interventions and their associated risks.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
